Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research ...

Determined Stoke City fan Paul Parsons has been clocking up the miles as he looks to score for charity after being inspired by his friend's brave daughter. The 46-year-old had this week set off from ...

LVEF (Left Ventricular Ejection Fraction): Percentage measure of how much blood the left ventricle pumps out with each ...

Good afternoon, and welcome to Cumberland Pharmaceuticals 2025 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on its website for 1 year ...

Controversial Yemassee 'monkey farm' announces plan to house retired scientific research monkeys from other facilities in the ...

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities ...

Controversial Yemassee 'monkey farm' announces plan to house retired scientific research monkeys from other facilities in the wake of federal funding cuts.

Last week, the FDA made its one pivotal trial policy official, sparking myriad questions from industry leaders, including around specific evidence required for the single study and why it hasn’t been ...

Scholar Rock’s latest earnings call struck a cautiously optimistic tone, with management emphasizing regulatory traction, a deepening neuromuscular pipeline, and a visibly maturing commercial ...

Leadership today looks different than it did a decade ago. These ten women are building movements, challenging industr ...

Bureaucracy's Rot Runs Amok at FDA ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...